Clinuvel Pharmaceuticals Limited Share Price
Stocks
CUV
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.15 AUD | -0.49% |
|
+2.27% | -18.50% |
| 06-16 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| 04-28 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
| Market Cap | 514M 355M 312M 288M 269M 505M 33.45B 3.46B 1.34B 16.5B 1.33B 1.3B 57.4B | P/E 2026 * |
14.3x | P/E 2027 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise Value | 261M 180M 158M 146M 137M 256M 16.95B 1.75B 680M 8.36B 675M 660M 29.09B | EV / Sales 2026 * |
2.62x | EV / Sales 2027 * | 2.17x |
| Free-Float |
83.79% | Yield 2026 * |
0.6% | Yield 2027 * | 0.78% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -0.44% | ||
| 1 week | +2.27% | ||
| Current month | +11.23% | ||
| 1 month | +14.49% | ||
| 3 months | +3.10% | ||
| 6 months | -21.03% | ||
| Current year | -18.50% |
| 1 week | 9.73 |  | 10.3 |
| 1 month | 8.35 | | 10.3 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 4.1 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 31/10/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 29/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 28/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 22/09/2019 |
| Chairman | - | 31/12/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/10/24 | Buy | Director | 8,333 | 0.0166% | ||
| 26/11/23 | Fiscal year | Chief Executive Officer | 301,125 | 0.6094% | ||
| 26/11/23 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.49% | +2.27% | +0.84% | -41.20% | 348M | |
| +0.87% | +2.55% | +19.37% | -20.05% | 62.88B | |
| +1.31% | +1.03% | +54.22% | +204.73% | 54.54B | |
| +8.80% | +38.50% | +38.50% | +38.50% | 38.44B | |
| +2.35% | +9.02% | -50.59% | -57.92% | 37.17B | |
| +1.22% | +0.46% | +58.02% | -29.85% | 29.11B | |
| -0.95% | -2.23% | +125.45% | -49.01% | 24.2B | |
| +3.89% | +9.57% | +57.17% | +73.67% | 20.86B | |
| +1.90% | +4.14% | -5.05% | +155.99% | 16.96B | |
| +1.03% | +6.99% | +69.37% | +123.53% | 16.6B | |
| Average | +2.01% | +2.37% | +36.73% | +39.84% | 30.11B | |
| Weighted average by Cap. | +2.32% | +1.65% | +35.73% | +44.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.46M 68.61M 60.41M 55.72M 52.11M 97.64M 6.47B 670M 259M 3.19B 258M 252M 11.1B | 105M 72.68M 63.99M 59.02M 55.2M 103M 6.85B 709M 275M 3.38B 273M 267M 11.76B |
| Net income | 35.97M 24.81M 21.84M 20.15M 18.84M 35.31M 2.34B 242M 93.79M 1.15B 93.15M 91.13M 4.01B | 38.2M 26.35M 23.2M 21.4M 20.01M 37.5M 2.48B 257M 99.61M 1.23B 98.94M 96.79M 4.26B |
| Net Debt | -254M -175M -154M -142M -133M -249M -16.5B -1.71B -662M -8.14B -657M -643M -28.31B | -286M -197M -174M -160M -150M -281M -18.6B -1.93B -746M -9.17B -741M -725M -31.92B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/06/26 | A$10.15 | -0.49% | 41,525 |
| 24/06/26 | A$10.20 | +2.51% | 94,852 |
| 23/06/26 | A$9.950 | -2.16% | 95,007 |
| 22/06/26 | A$10.17 | -1.26% | 72,231 |
| 19/06/26 | A$10.30 | +3.73% | 278,606 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
